Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells

Oncology Research

Volumn 12, Issue 9-10, 2000, Pages 397-408

  Andrei, Graciela ^a   Snoeck, Robert ^a   Schols, Dominique ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Apoptosis; HPMPC (cidofovir); Human papillomavirus (HPV)

Indexed keywords

ANTIVIRUS AGENT; CASP3 PROTEIN, HUMAN; CASPASE; CASPASE 3; CIDOFOVIR; CYTOSINE; DNA FRAGMENT; DRUG DERIVATIVE; HRAS PROTEIN, HUMAN; LIPOCORTIN 5; ORGANOPHOSPHORUS COMPOUND; PHOSPHATIDYLSERINE; PHOSPHONIC ACID DERIVATIVE; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL LINE; CELL NUCLEUS; CYTOLOGY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; KERATINOCYTE; METABOLISM; PAPILLOMA VIRUS; TIME; VIROLOGY;

ANNEXIN A5; ANTIVIRAL AGENTS; APOPTOSIS; CASPASE 3; CASPASES; CELL CYCLE; CELL LINE; CELL NUCLEUS; CELLS, CULTURED; CYTOSINE; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; KERATINOCYTES; ORGANOPHOSPHORUS COMPOUNDS; PAPILLOMAVIRIDAE; PHOSPHATIDYLSERINES; PHOSPHONIC ACIDS; PROTO-ONCOGENE PROTEINS P21(RAS); S PHASE; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034575076     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747855     Document Type: Article

References (47)

1. Becker, T. M.; Stone, K. M.; Alexander, E. R. Genital human papillomavirus infection: A growing concern. Obstet. Gynecol. Clin. North Am. 14:389-396; 1987.
2. Zur Hausen, H. Viruses in human cancer. Science 254:1167-1173; 1991.
3. Steele, C.; Shillitoe, E. J. Viruses and oral cancer. Crit. Rev. Oral Biol. Med. 2:153-175; 1991.
4. De Villers, E. M. Heterogeneity of the human papillomavirus group. J. Virol. 63:4898-4903; 1989.
5. Schiffman, M. H. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J. Natl. Cancer Inst. 84:394-397; 1992.
6. Phelps, W. C.; Barnes, J. A.; Lobe, D. C. Molecular targets for human papillomaviruses: Prospects for antiviral therapy. Antiviral Chem. Chemother. 9:359-377; 1998.
7. Snoeck, R.; Andrei, G.; De Clercq, E. Specific therapies against papilloma virus. Curr. Opin. Infect. Dis. 11:733-737; 1999.
8. Snoeck, R.; Andrei, G.; De Clercq, E. Cidofovir in the treatment of HPV-associated lesions. Verh. K. Acad. Geneesk. Belg. 63: 93-122; 2001.
9. Andrei, G.; Snoeck, R.; Piette, J.; Delvenne, P.; De Clercq, E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 10:523-531; 1998.
10. Andrei, G.; Snoeck, R.; Piette, J.; Delvenne, P.; De Clercq, E. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic-nude mice. Oncol. Res. 10:533-539; 1998.
11. Gilles, C.; Piette, J.; Rombouts, S.; Laurent, C.; Foidart, J.-M. Immortalization of human cervical keratinocytes by human papillomavirus type 33. Int. J. Cancer 53:872-879; 1993.
12. Wyllie, A. H.; Morris, R. G.; Smith, A. L.; Dunlop, D. Chromatin cleavage in apoptosis: Association with condensed chromatin morphology and dependence on macromolecular synthesis. J. Pathol. 142:67-77; 1984
13. Kerr, J. F. R.; Harmon, B. V. Definition and incidence of apoptosis: An historical perspective. In: David, L., ed. Apoptosis: The molecules basis of cell death. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1991:5-29.
14. Gerner, C.; Seelos, C.; Sauermann, G. Alteration of nuclear matrix protein composition during apoptosis in rat embryo cells. Exp. Cell Res. 238:472-480; 1998.
15. Gueth-Hallonet, C.; Weber, K.; Osborn, M. Cleavage of the nuclear matrix protein NuMA during apoptosis. Exp. Cell Res. 233: 21-24; 1997.
16. Darmon, A. J.; Nicholson, D. W.; Bleakkley, R. C. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 337:446-448; 1995.
17. Nicholson, D. W.; Ali, A.; Thornberry, N. A.; Vaillancourt, J. P.; Ding, C. K.; Gallant, M.; Gareau, Y.; Griffin, P. R.; Labelle, M.; Lazebnik, Y. A.; Munday, N. A.; Raji, S. M.; Smulson, M. E.; Yamin, T. T.; Yu, V. L.; Miller, D. K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37-43; 1995.
18. Alnemri, E.; Livingston, D.; Nicholson, D.; Salvesen, G.; Thornberg, N.; Wong, W.; Yuang, J. Human ICE/CED-3 protease nomenclature. Cell 87:171; 1996.
19. Fadok, V. A.; Voelker, D. R.; Campbell, P. A.; Cohen, J. J.; Bratton, D. L.; Henson, P. M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148:2207-2216; 1992.
20. Martin, S. J.; McGahon, A. J.; Rader, J. A.; Van Schie, R. C.; La Face, D. M.; Green, D. R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition of overexpression of Bcl-2 and Abl. J. Exp. Med. 182:1545-1556; 1995.
21. Van Engeland, M.; Nieland, L. J.; Ramaekers, F. C.; Schutte, B.; Reutelingsperger, C. P. Annexin V-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31:1-9; 1998.
22. Rudel, T.; Bokoch, G. M. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 276:1571-1574; 1997.
23. Neyts, J.; Sadler, R.; De Clercq, E.; Raab-Traub, N.; Pagano, J. S. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res. 58: 384-388; 1998.
24. Majno, G.; Joris, I. Apoptosis, oncosis and necrosis: An overview of cell death. Am. J. Pathol. 146:3-15; 1995.
25. Darzynkiewicz, Z. Apoptosis in tumor strategies: Modulation of cell cycle or differentiation. J. Cell. Biochem. 58:151-159; 1995.
26. Kerr, J. F. R.; Winterfold, C. M.; Harmon, B. V. Apoptosis: Its significance in cancer and cancer therapy. Cancer 73:2013-2026; 1994.
27. Johnson, J. A.; Gangemi, J. D. Selective inhibition of human papilloma virus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Antimicrob. Agents Chemother. 43:1198-1205; 1999.
28. Sherr, C. J.; Roberts, J. M. Inhibitors of mammalian G1 cyclin dependent kinases. Genes Dev. 9:1149-1163; 1995.
29. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88:323-331; 1997.
30. Agarwall, M. L.; Taylor, W. R.; Chemov, M. V.; Chernov, O. L.; Stark, G. R. The p53 network. J. Biol. Chem. 273:4; 1998.
31. Werness, B. A.; Levine, D. J.; Howley, P. M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79; 1990.
32. Heck, D. V.; Yee, C. L.; Howley, P. M.; Munger, K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncproteins of the human papillomaviruses. Proc. Nat. Acad. Sci. USA 89:4442-4446; 1992.
33. Lechner, M. S.; Mack, D. H.; Finicle, A. B.; Crook, T.; Vousden, K. H.; Laimins, L. A. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated regression of transcription. EMBO J. 11:3045-3052; 1992.
34. Scheffner, M.; Werness, B. A.; Huibregtse, J. M.; Levine, A. J.; Horsley, P. M. The E4 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136; 1990.
35. Jones, D. L.; Munger, K. Interactions of the human papillomavirus E7 protein with cell cycle regulators. Semin. Cancer Biol. 7:327-337; 1996.
36. Jones, D. L.; Alani, R. M.; Munger, K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 11:2102-2111; 1997.
37. Funk, J. O.; Waga, S.; Harry, J. B.; Espling, E.; Stillman, B.; Galloway, D. A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncorprotein. Genes Dev. 11:2090-2100; 1997.
38. Schwarz, E.; Freese, U. K.; Gissmann, L.; Mayer, W.; Roggenberck, B.; Stremlau, A.; Zur Hausen, H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314:111-114; 1985.
39. Yee, C.; Krishan-Hewlett, I.; Baker, C. C.; Sehlegel, R.; Howley, P. M. Presence and expression of human papillomavims sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119:361-366; 1985.
40. Naesens, L.; Snoeck, R.; Andrei, G.; Balzarini, J.; Neyts, J.; De Clercq, E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. 8:1-23; 1997.
41. Safrin, S.; Cherrington, J.; Jaffe, H. S. Clinical uses of cidofovir. Rev. Med. Virol. 7:145-156; 1997.
42. Van Cutsem, E.; Snoeck, R.; Van Ranst, M.; Fiten, P.; Opdenakker, G.; Geboes, K.; Janssens, J.; Rutgeerts, P.; Vantrappen, G.; De Clercq, E. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J. Med. Virol. 45: 230-235; 1995.
43. Snoeck, R.; Wellens, W.; Desloovere, C.; Van Ranst, M.; Naesens, L.; De Clercq, E.; Feenstra, L. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J. Med. Virol. 54:219-225; 1998.
44. Pransky, S. M.; Magit, A. E.; Kearns, D. B.; Kang, D. R.; Duncan, N. O. Intralesion cidofovir for recurrent respiratory papillomatosis in children. Arch. Otolaryngol. Head Neck Surg. 125:1143-1148; 1999.
45. Snoeck, R.; Van Ranst, M.; Andrei, G.; De Clercq, E.; De Wit, S.; Poncin, M.; Clumeck, N. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N. Engl. J. Med. 333:943-944; 1995.
46. Snoeck, R.; Bossens, M.; Parent, D.; Delaere, B.; Degreef, H.; Van Ranst, M.; Noel, J.C.; Wulpohn, M.; Rooney, J. F.; Jaffe, H. S.; De Clercq, E. A phase II double-blind-placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin. Infect. Dis. 33:597-602; 2001.
47. Zabawski, E. J., Jr.; Sands, B.; Goetz, D.; Naylor, M.; Cockerell, C. J. Treatment of verruca vulgaris with topical cidofovir. J. Am. Med. Assoc. 278:1236; 1997.